Clinical Trial Update: Clinical Study of Xinmailong Injection on Reducing Cardiovascular Toxicity in Adjuvant Chemotherapy in Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating Xinmailong Injection to reduce cardiovascular toxicity from adjuvant chemotherapy in breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasms
• Cardiac Event

Drugs mentioned

• Xinmailong Injection

Snippet

Sponsor: Peking Union Medical College | Conditions: Breast Neoplasms, Cardiac Event | Phase 2 | Status: UNKNOWN